• news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

o2h-ventures

  • news
    • Press releases
    • Blog
    • Media Coverage
    • Event
  • Documents
  • About
  • Team
  • funds
    • o2h human health KI EIS
    • o2h human health SEIS
    • o2h human health EIS
  • Portfolio
  • knowledgehub
    • what is KI EIS fund?
  • Contact

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more

o2h Human Health EIS Fund leads an investment into Kuano, using quantum and AI to accelerate the development of new medicine.
o2h Human Health EIS Fund leads an investment into Kuano, using quantum and AI to accelerate the development of new medicine.
Feb 25 2021

London, UK, 25 Feb 2021: The o2h human health EIS Fund is pleased to announce an investment in Kuano, a London based company using quantum and AI to simulate  drug and virus interactions to identify drugs to shortcut the drug discovery process and improve the chances of success. 

Kuano has identified four attractive drug targets with huge commercial benefit to demonstrate their technology platform and if successful these could be licensed to big pharma. Simultaneously they will seek collaborative deals with pharma and biotech to leverage their technology platform to support their on-going innovations. 

o2h Ventures has a track record of nurturing and investing in some of the most innovative early stage biotech companies in the UK. Joining o2h Ventures in this investment round is Meltwind, Syndicate Room and Cambridge Angels. 

Sunil Shah, CEO at o2h Ventures said: “We are very pleased to back Kuano in this venture. Being able to more accurately understand and predict subtle changes around enzyme’s active sites could unlock faster opportunities to push inhibitors for difficult drug targets through discovery and development. Vid and Dave using their knowledge of quantum physics and Parminder with her previous big pharma and biotech drug discovery experience make a great team to both develop the platform and advance the drug assets from this. I am very much looking forward to joining the board and supporting this venture”.

Dr. Vid Stojevic, Co-Founder CEO of Kuano, said: “o2h Ventures have already been supportive over the last six months to develop our business model and also to identify high value drug targets. I am very excited to bring on a fund with the deep expertise and network that o2h Ventures can bring in the biotech space ”.

Editor’s Note:

About o2h Ventures:

The o2h human health EIS Fund is the first S/EIS fund in the UK solely focused on investing in EIS and/or SEIS qualifying seed stage companies covering novel drug discovery & AI, digital therapeutics and enabling services.

The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.

For more information about o2h Ventures, please visit www.o2hventures.com

Media Contact:

Ajit Singh,

Marketing Manager,

ajit@o2h.com

About Kuano:

Kuano is an artificial intelligence company using quantum computing to create molecular design solutions that is headquartered in London, England and was founded in 2020 by Vid Stojevic, David Wright, Parminder Ruprah, and Jarryl D’Oyley.

Kuano focuses on developing enzyme inhibitors using artificial intelligence and quantum computing simulations for pharmaceutical, crop protection, and industrial chemistry applications. Properties of enzyme inhibitors being selected for by Kuano include enzyme binding transition states, enzyme transition state selectivity, and ability to maintain enzyme function regardless of possible mutations. Kuano manipulates enzyme properties to create enzyme inhibitors with more desirable dosage levels, toxicity levels, and resistance levels to mutations.

Examples of pilot projects worked on by Kuano include: designing transition state inhibitors for target enzymes, discovery requirements for resistance repair for specific compounds and classes of compounds, enzyme inhibition predictions, identifying distinct chemotypes, and expanding knowledge of a chemotype and the creation of a soft focus screening library.

For more information visit: https://www.kuano.ai/

Media Contact 

Vid Stojevic

Co-Founder and CEO at Kuano

vid.stojevic@kuano.ai

 

Connect with us
  • linkedin
  • youtube
  • email
o2h-ventures
recent press releases
  • o2h-ventures o2h Ventures makes an SEIS Investment into Five Alarm Bio to strengthen anti-ageing science 28 Feb 2023
  • o2h-ventures Exciting news as o2h Ventures’ portfolio company Small Pharma, unveils positive top-line results of their Phase IIa clinical trial for treating MDD 31 Jan 2023
  • o2h-ventures o2h Ventures backed Kuano wins Innovate UK funding for designing the next generation of cancer drugs 18 Jan 2023
o2h-ventures
o2h Ventures Limited
Hauxton House,
The Mill SciTech Park,
Mill Lane, Hauxton
Cambridge
CB22 5HX
07341612481
invest@o2h.com
about
  • about us
  • team
  • portfolio
  • funds
insights and news
  • knowledge hub
  • press releases
  • blog
  • event
  • documents
connect with us
  • linkedin
  • youtube
  • email
Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums.
Your capital is at risk. Investing in early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high net worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
o2h ventures Limited is regulated and authorised by the Financial Conduct Authority (FRN 812245). Capital at risk, only suitable for high net worth and sophisticated investors
© 2025 o2h ventures
  • Privacy Policy
  • Blog
  • Contact us

Risk Information

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk

What are the key risks?

1 – You could lose all the money you invest

• If the business you invest in fails, you are likely to lose 100% of the money you invest. Most start-up businesses fail.

2 – You are unlikely to be protected if something goes wrong

• Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker here. (https://www.fscs.org.uk/check/investment-protection-checker)

• Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated firm, FOS may be able to consider it. Learn more about FOS protection here. (https://www.financial-ombudsman.org.uk/consumers)

3 – You won’t get your money back quickly

• Even if the business you invest in is successful, it may take several years to get your money back. You are unlikely to be able to sell your investment early.

• The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.

• If you are investing in a start-up business, you should not expect to get your money back through dividends. Start-up businesses rarely pay these.

4 – Don’t put all your eggs in one basket

• Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well.

• A good rule of thumb is not to invest more than 10% of your money in high-risk investments (https://www.fca.org.uk/investsmart/5-questions-ask-you-invest)

5 – The value of your investment can be reduced

• The percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.

• These new shares could have addition rights that your shares don’t have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

If you are interested in learning more about how to protect yourself, visit the FCA’s website here (https://www.fca.org.uk/investsmart)